Display options
Cite
Morillas C, Feliciano R, Catalina PF, et al. Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. Patient Prefer Adherence. 2015;9:1443-58doi: 10.2147/PPA.S88022.
Morillas, C., Feliciano, R., Catalina, P. F., Ponte, C., Botella, M., Rodrigues, J., Esmatjes, E., Lafita, J., Lizán, L., Llorente, I., Morales, C., Navarro-Pérez, J., Orozco-Beltran, D., Paz, S., Ramirez de Arellano, A., Cardoso, C., & Tribaldos Causadias, M. (2015). Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. Patient preference and adherence, 91443-58. https://doi.org/10.2147/PPA.S88022
Morillas, Carlos, et al. "Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment." Patient preference and adherence vol. 9 (2015): 1443-58. doi: https://doi.org/10.2147/PPA.S88022
Morillas C, Feliciano R, Catalina PF, Ponte C, Botella M, Rodrigues J, Esmatjes E, Lafita J, Lizán L, Llorente I, Morales C, Navarro-Pérez J, Orozco-Beltran D, Paz S, Ramirez de Arellano A, Cardoso C, Tribaldos Causadias M. Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. Patient Prefer Adherence. 2015 Oct 14;9:1443-58. doi: 10.2147/PPA.S88022. eCollection 2015. PMID: 26508841; PMCID: PMC4612138.
Copy Download .nbib Format: NLM
Share it on

Patient Prefer Adherence. 2015 Oct 14;9:1443-58. doi: 10.2147/PPA.S88022. eCollection 2015.

Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment.

Patient preference and adherence

Carlos Morillas, Rosa Feliciano, Pablo Fernández Catalina, Carla Ponte, Marta Botella, João Rodrigues, Enric Esmatjes, Javier Lafita, Luis Lizán, Ignacio Llorente, Cristóbal Morales, Jorge Navarro-Pérez, Domingo Orozco-Beltran, Silvia Paz, Antonio Ramirez de Arellano, Cristina Cardoso, Maribel Tribaldos Causadias

Affiliations

  1. Hospital Universitario Dr Peset, Valencia, Spain.
  2. USF São Domingos, Santarém, Portugal.
  3. Hospital Montecelo de Pontevedra, Galicia, Spain.
  4. USF Porta do Sol, Matosinhos, Portugal.
  5. Hospital Universitario Principe de Asturias, Madrid, Spain.
  6. USF Serra da Lousã, Lousã, Portugal.
  7. Hospital Clinic, Barcelona, Spain.
  8. Hospital de Navarra, Navarra, Spain.
  9. Outcomes'10, Universidad Jaume I, Castellón, Spain.
  10. Hospital Universitario Nuestra Señora de la Candelaria, Canarias, Spain.
  11. Hospital Universitario Virgen de la Macarena, Sevilla, Spain.
  12. INCLIVA, CIBERESP, Universidad de Valencia, Valencia, Spain.
  13. Sociedad Española de Medicina Familiar y Comunitaria, Valencia, Spain.
  14. Novo Nordisk EU-HEOR Europe, Madrid, Spain.
  15. Novo Nordisk, Lisbon, Portugal.

PMID: 26508841 PMCID: PMC4612138 DOI: 10.2147/PPA.S88022

Abstract

OBJECTIVE: To assess Spanish and Portuguese patients' and physicians' preferences regarding type 2 diabetes mellitus (T2DM) treatments and the monthly willingness to pay (WTP) to gain benefits or avoid side effects.

METHODS: An observational, multicenter, exploratory study focused on routine clinical practice in Spain and Portugal. Physicians were recruited from multiple hospitals and outpatient clinics, while patients were recruited from eleven centers operating in the public health care system in different autonomous communities in Spain and Portugal. Preferences were measured via a discrete choice experiment by rating multiple T2DM medication attributes. Data were analyzed using the conditional logit model.

RESULTS: Three-hundred and thirty (n=330) patients (49.7% female; mean age 62.4 [SD: 10.3] years, mean T2DM duration 13.9 [8.2] years, mean body mass index 32.5 [6.8] kg/m(2), 41.8% received oral + injected medication, 40.3% received oral, and 17.6% injected treatments) and 221 physicians from Spain and Portugal (62% female; mean age 41.9 [SD: 10.5] years, 33.5% endocrinologists, 66.5% primary-care doctors) participated. Patients valued avoiding a gain in bodyweight of 3 kg/6 months (WTP: €68.14 [95% confidence interval: 54.55-85.08]) the most, followed by avoiding one hypoglycemic event/month (WTP: €54.80 [23.29-82.26]). Physicians valued avoiding one hypoglycemia/week (WTP: €287.18 [95% confidence interval: 160.31-1,387.21]) the most, followed by avoiding a 3 kg/6 months gain in bodyweight and decreasing cardiovascular risk (WTP: €166.87 [88.63-843.09] and €154.30 [98.13-434.19], respectively). Physicians and patients were willing to pay €125.92 (73.30-622.75) and €24.28 (18.41-30.31), respectively, to avoid a 1% increase in glycated hemoglobin, and €143.30 (73.39-543.62) and €42.74 (23.89-61.77) to avoid nausea.

CONCLUSION: Both patients and physicians in Spain and Portugal are willing to pay for the health benefits associated with improved diabetes treatment, the most important being to avoid hypoglycemia and gaining weight. Decreased cardiovascular risk and weight reduction became the third most valued attributes for physicians and patients, respectively.

Keywords: HbA1c; cardiovascular risk; diabetes; discrete choice model; hypoglycemia; preferences; weight; willingness to pay

References

  1. Appl Health Econ Health Policy. 2003;2(1):55-64 - PubMed
  2. Diabetes Care. 2004 Aug;27(8):2067-73 - PubMed
  3. Value Health. 2004 Jul-Aug;7(4):442-54 - PubMed
  4. Health Econ. 2007 Aug;16(8):827-40 - PubMed
  5. Curr Med Res Opin. 2007 Sep;23(9):2051-62 - PubMed
  6. Med Clin (Barc). 2007 Sep 15;129(9):352-5 - PubMed
  7. Expert Rev Pharmacoecon Outcomes Res. 2002 Aug;2(4):319-26 - PubMed
  8. Health Econ. 2011 Mar;20(3):273-86 - PubMed
  9. Curr Med Res Opin. 2010 Apr;26(4):917-23 - PubMed
  10. Health Econ. 2011 Mar;20(3):323-30 - PubMed
  11. Psychol Rev. 2010 Apr;117(2):440-63 - PubMed
  12. J Manag Care Pharm. 2010 Oct;16(8):616-28 - PubMed
  13. Health Qual Life Outcomes. 2010 Nov 04;8:125 - PubMed
  14. Patient Prefer Adherence. 2010 Dec 08;4:433-40 - PubMed
  15. Value Health. 2011 Jun;14(4):403-13 - PubMed
  16. Curr Med Res Opin. 2011 Nov;27(11):2175-83 - PubMed
  17. Diabetologia. 2012 Jan;55(1):88-93 - PubMed
  18. Ann N Y Acad Sci. 2011 Oct;1235:44-56 - PubMed
  19. J Med Econ. 2012;15(2):261-3 - PubMed
  20. Health Econ. 2012 Feb;21(2):145-72 - PubMed
  21. J Med Econ. 2012;15 Suppl 2:1-5 - PubMed
  22. Value Health. 2013 Jan-Feb;16(1):3-13 - PubMed
  23. J Diabetes Metab Disord. 2012 Oct 01;11(1):17 - PubMed
  24. Appl Health Econ Health Policy. 2013 Jun;11(3):163-80 - PubMed
  25. Diabetes Metab. 2013 Oct;39(5):397-403 - PubMed
  26. Diabetes Ther. 2013 Dec;4(2):175-94 - PubMed
  27. Patient Prefer Adherence. 2013 Sep 18;7:937-49 - PubMed
  28. J Med Econ. 2013 Nov;16(11):1357-65 - PubMed
  29. Diabetes Ther. 2013 Dec;4(2):443-59 - PubMed
  30. Lancet. 2014 Mar 22;383(9922):1068-83 - PubMed
  31. Diabetes Care. 2014 Jan;37 Suppl 1:S14-80 - PubMed
  32. Int J Clin Pract. 2014 Jun;68(6):682-91 - PubMed
  33. Diabetes Res Clin Pract. 2014 Feb;103(2):137-49 - PubMed
  34. Int J Med Inform. 2014 Jul;83(7):517-28 - PubMed
  35. Diabetes Metab Syndr Obes. 2014 May 23;7:169-83 - PubMed
  36. Pharmacoeconomics. 2014 Sep;32(9):883-902 - PubMed
  37. BMC Health Serv Res. 2014 Sep 01;14:367 - PubMed
  38. Patient Prefer Adherence. 2014 Dec 04;8:1653-64 - PubMed
  39. J Diabetes. 2015 Nov;7(6):864-71 - PubMed
  40. Patient. 2015 Oct;8(5):373-84 - PubMed

Publication Types